With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma

A slow January IPO market has leaned on biopharma and life‑sciences issuers — several backed by hedge fund specialists — for the few deals getting done.

Stephen Taub January 29, 2026

With the broader IPO calendar still muted, biopharma and life sciences issuers are cautiously testing the waters — and early trading in one name is giving the sector a modest tailwind. So far, just six companies have gone public in January, with four more slated to

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.15.02 build:2026-02-04 Login